Categories: The Charlton Centre

Ontario Provides Coverage for the Osteoporosis Medication Evenity (romosozumab)

Treating osteoporosis is vital to preventing fractures. Once a person has experienced a fracture of a weakened bone, especially after the age of 65, their risk of having another fracture in the next 1-2 years is greatly increased. Menopausal women who fall in this very high fracture risk category will now have access to the advanced therapy, Evenity. This funding is limited to those who have not had a previous prescription medication for osteoporosis as using a medication that builds new bone as a first treatment is much more successful at preventing fractures.

Evenity is typically given as two injections once a month for a year. After the year, the person would then take a different medication to prevent bone-eating, to maintain the growth they received on Evenity.

The medication will still require an application to the government to verify that the person meets the criteria for having a high risk of fracture.

We are very excited about this new coverage for such an effective osteoporosis treatment.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

admin

Recent Posts

Winrevair: A New Treatment Option for Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…

1 week ago

New Biologic Treatment for PMR (Polymyalgia Rheumatica)

Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…

3 weeks ago

Expanded Protection: RSV Vaccine Now Approved for More Adults

Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…

1 month ago

Rinvoq: A New Oral Option for Giant Cell Arteritis

Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…

2 months ago

World Arthritis and Mental Health Day: October 2025

Every year on October 12, World Arthritis Day raises awareness about the millions of people…

2 months ago

Tremfya: New Dosing Options for Crohn’s Disease and Ulcerative Colitis

Tremfya (guselkumab) has been available for several years to treat plaque psoriasis and psoriatic arthritis.…

3 months ago